Janus Henderson Group plc Increases Stake in Immix Biopharma, Inc. to 13.0%

On June 5, 2026, Janus Henderson Group plc (JHG) filed a Schedule 13G/A with the SEC, reporting a significant increase in its stake in Immix Biopharma, Inc. (IMMX). As of the event date on May 29, 2026, the firm beneficially owns 9,090,732 shares of common stock, representing 13.0% of the company. This marks a substantial increase from the 4,802,002 shares (9.1%) previously reported. Janus Henderson Group plc serves as the ultimate parent company for various investment advisers, including Janus Henderson Investors US LLC and several international subsidiaries. The shares are held across various managed portfolios, with the Janus Henderson Biotech Innovation Master Fund Ltd. noted as having the right to receive dividends and sale proceeds for more than 5% of the outstanding stock. The filing indicates that JHG holds shared voting and dispositive power over the entire 9,090,732 shares. The acquisition was made in the ordinary course of business without the intent to influence or change the control of the issuer.